PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.
http://www.peervoice.com
Immunotherapies for Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Which Antibodies for Which Patients?
Visit https://www.peervoice.com/RJT860 to view the entire programme with slides. After completing “Immunotherapies for Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Which Antibodies for Which Patients?”, participants will be able to: Explain the unmet medical needs in diffuse large B-cell lymphoma (DLBCL); Assess the latest clinical data for novel and emerging antibody strategies for the treatment of relapsed/refractory DLBCL; Translate available clinical data for immunotherapeutic strategies into practical guidance for the clinic in order to maximise patient outcomes.